These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21480769)

  • 1. Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention.
    Ahn SG; Lee SH; Sung JK; Kim JY; Yoon J
    Platelets; 2011; 22(4):305-7. PubMed ID: 21480769
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients undergoing percutaneous coronary intervention.
    Jang J; Lim J; Chang K; Kim Y; Kim M; Park HI; Kim J; Shin S
    J Clin Lab Anal; 2012 Jul; 26(4):262-6. PubMed ID: 22811359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of initial clinical presentation on clopidogrel low response.
    Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM; Lemesle G
    Arch Cardiovasc Dis; 2013 Nov; 106(11):593-600. PubMed ID: 24070598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
    Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver Function is Associated With Response to Clopidogrel Therapy in Patients Undergoing Angioplasty and Stenting.
    Gremmel T; Mueller M; Koppensteiner R; Panzer S
    Angiology; 2016 Oct; 67(9):835-9. PubMed ID: 26416820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does hemodialysis affect clopidogrel resistance as measured by VerifyNow P2Y12 test?
    Geara AS; Ayoub I; Abi Rached J; Siddique MN; Ghimire P; El-Sayegh S
    Am J Cardiol; 2011 Apr; 107(7):1103-4. PubMed ID: 21419895
    [No Abstract]   [Full Text] [Related]  

  • 8. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics.
    Hernandez-Suarez DF; Scott SA; Tomey MI; Melin K; Lopez-Candales A; Buckley CE; Duconge J
    Ther Adv Cardiovasc Dis; 2017 Sep; 11(9):235-241. PubMed ID: 28675986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
    Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays.
    Consuegra-Sánchez L; López-Palop R; Cano P; Carrillo P; Picó F; Villegas M; Sanchis J; Kaski JC
    J Thromb Haemost; 2013 Feb; 11(2):379-81. PubMed ID: 23253198
    [No Abstract]   [Full Text] [Related]  

  • 12. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.
    Geisler T; Booth J; Tavlaki E; Karathanos A; Müller K; Droppa M; Gawaz M; Yanez-Lopez M; Davidson SJ; Stables RH; Banya W; Zaman A; Flather M; Dalby M
    PLoS One; 2015; 10(8):e0135037. PubMed ID: 26317618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness.
    Kakouros N; Kickler TS; Laws KM; Rade JJ
    J Thromb Haemost; 2013 Oct; 11(10):1814-22. PubMed ID: 24118870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists.
    So DYF; Bagai A; Tran U; Verma S; Mehta SR
    Curr Opin Cardiol; 2017 Sep; 32(5):617-626. PubMed ID: 28661903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Aitmokhtar O; Paganelli F; Benamara S; Azaza A; Bonello L; Hamza O; Seddiki S; Benathmane T; Saidane M; Bouzid A; Kara M; Sik A; Azzouz A; Harbi F; Monsuez JJ; Benkhedda S
    Arch Cardiovasc Dis; 2017 Nov; 110(11):626-633. PubMed ID: 28583820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
    Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenoreceptors, platelet reactivity and clopidogrel resistance.
    Xiang YZ
    Thromb Haemost; 2008 Nov; 100(5):729-30. PubMed ID: 18989508
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.
    Reed GW; Cannon CP; Waalen J; Teirstein PS; Tanguay JF; Berger PB; Angiolillo DJ; Price MJ
    Catheter Cardiovasc Interv; 2017 Feb; 89(2):190-198. PubMed ID: 26909669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
    Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
    Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.